# Analyze Iss Antitrust Transaction Structure > Closes gaps in deal-structure antitrust risk analysis including hell-or-high-water provision adequacy, reverse termination fee sufficiency, outside date feasibility, and hot-document identification. - Skill: `finchipaiorg/analyze-iss-antitrust-transaction-structure` (Agent Skill) - Install (CLI): `npx skillmds@latest add finchipaiorg/analyze-iss-antitrust-transaction-structure` - Raw SKILL.md: https://api.skillmd.com/api/skills/finchipaiorg/analyze-iss-antitrust-transaction-structure/raw - Safety review: pending - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: FinchipAIOrg (https://skillmd.com/u/finchipaiorg) - Updated: 2026-09-22 - Page: https://skillmd.com/skills/finchipaiorg/analyze-iss-antitrust-transaction-structure --- # Skill: Antitrust Transaction Structure Analysis ## 1. Subject-matter triage - Treat the assignment as an antitrust deal-review memo, not a generic diligence summary. - Identify whether the source set includes merger agreement drafts, board decks, banker materials, emails, schedules, and regulatory strategy materials. - Separate transactional structure issues from substantive competition issues, then connect them back to clearance risk and closing mechanics. - If multiple jurisdictions, business lines, or product overlaps are present, analyze each as a distinct clearance track rather than collapsing them into one global assessment. ## 2. Failure modes the skill is correcting - The analysis stops at “antitrust risk exists” without tying that risk to a specific remedy posture, filing path, or closing consequence. - The analysis ignores the practical force of a reverse termination fee and whether it is large enough to change behavior rather than merely allocate downside. - The analysis treats a divestiture cap, remedy carve-out, or consent limitation as boilerplate instead of testing whether it weakens the buyer’s clearance commitment. - The analysis misses whether the outside date leaves enough runway for clearance review, second requests, remedy negotiation, or post-clearance waiting periods. - The analysis overlooks internal materials that frame the deal as a pricing, capacity, market-power, or competitor-removal story and therefore require careful document handling. - The analysis mentions overlap but does not connect overlap to likely unilateral, coordinated, or vertical theories of harm. - The analysis identifies concerns but does not end with concrete recommendations on filings, term changes, preservation, and remedy strategy. ## 3. Legal frameworks / domain conventions that apply - Use the relevant merger-control standard for each jurisdiction implicated by the deal; anchor the analysis in the governing competition statute and agency practice for that forum. - For U.S. review, frame the substantive analysis under Section 7 of the Clayton Act and the Hart-Scott-Rodino Act filing regime where applicable; for other jurisdictions, use the local merger-control statute and clearance test. - Assess concentration, overlap, and competitive effects using the standard merger-screen framework: relevant market, shares, concentration, entry, diversion, and likely remedy path. - Treat a hell-or-high-water commitment as meaningful only if it obligates the buyer to pursue and accept commercially reasonable remedies needed for clearance; remedy caps, asset exclusions, or “no structural divestiture” language may materially dilute it. - Evaluate a reverse termination fee as an incentive device: it should be measured against the transaction’s risk profile and closing economics, not treated as sufficient merely because it exists. - Test the outside date against expected agency timing, second-request exposure, litigation risk, and any post-clearance waiting period or local sequencing requirement. - Treat internal documents discussing pricing power, reduced competition, market control, customer capture, or competitor removal as hot documents relevant to intent and effects. - Treat non-compete and similar retention restrictions as part of the competition analysis where departing personnel or management could compete post-closing. - Use merger-specific remedy concepts: divestiture buyer viability, fix-it-first feasibility, conduct remedy limits, and whether the proposed buyer restores competitive conditions. ## 4. Analytical scaffolds 1. Map the transaction - Identify the parties, business lines, products, geography, and review jurisdictions. - Enumerate each overlap, adjacency, and customer-facing interaction before analyzing effects. 2. Assess substantive antitrust risk - Define the likely relevant market(s) at the level supported by the documents. - Analyze concentration, diversion, customer switching, capacity, and entry. - State the likely theory of harm for each overlap: unilateral effects, coordinated effects, foreclosure, or information-based concerns. 3. Test the documentary record for hot issues - Review board decks, banker books, management presentations, emails, and draft strategy materials for competition-sensitive language. - Flag each item by document type and why it is sensitive. - Recommend preservation, legal hold, and privilege review steps where the record suggests antitrust intent risk. 4. Analyze deal-protection mechanics - Evaluate whether the hell-or-high-water covenant is broad enough to require meaningful remedy pursuit. - Check whether any remedy cap, carve-out, or buyer consent right undermines the covenant. - Assess whether the reverse termination fee is large enough to create real clearance incentives. - Test whether the outside date accommodates the likely clearance path. 5. Evaluate remedies and filing strategy - Identify whether divestiture, conduct commitments, or behavioral undertakings are likely to be requested. - Assess potential remedy buyers for capability, independence, and operational fit. - Determine whether filings should be made early, simultaneously, sequentially, or with a hold-separate strategy. 6. Close each issue with consequences - For every issue, tie the concern to a source-document metric or transactional fact, cross-reference the clause or exhibit that affects it, and state the closing, regulatory, or litigation consequence. 7. Assign severity consistently - Use a defined ordinal severity scale throughout the memo and apply it uniformly to each issue. ## 5. Vertical / structural / temporal relationships - Identify how the merger agreement, disclosure schedules, internal strategy materials, and regulatory communications interact. - If one provision limits another, explain the hierarchy in practical terms: e.g., a remedy covenant may be narrowed by a cap, timing gate, or consent standard. - Track sequencing risk: signing, filing, waiting period, second request, remedy discussions, and closing should be analyzed in temporal order. - If the record contains multiple products, regions, or clearance authorities, analyze them separately first and then state the combined closing timetable. - Distinguish pre-signing risk flags from post-signing obligations so the memo does not conflate diligence concerns with covenants. ## 6. Output structure conventions - Begin with a short executive summary stating the overall antitrust risk level and the likely clearance posture. - Use a clear severity scale near the front of the memo and apply it to each issue consistently. - Organize the body in a conventional issues-memo shape: - Transaction overview and review scope - Competitive overlap and market context - Hot documents and document-handling risks - Deal-protection and closing-condition analysis - Remedies and filing strategy - Recommended actions - For each issue, include: - Severity - Legal basis with the controlling authority named - The relevant factual trigger from the documents - The interaction with another clause, schedule, or document - The downstream consequence for clearance, timing, or economics - Do not state antitrust conclusions in conclusory form without naming the governing statute, regulation, or doctrinal standard supporting them. - End with a Recommended Actions block that assigns each action to a responsible role and ties it to a transaction or regulatory milestone. - Include document-preservation and privilege-review steps whenever internal materials suggest competition-sensitive intent. - If the source set supports more than one filing path or remedy posture, list each path separately and compare the tradeoffs rather than selecting a single default.